Cambridge Trust Co. boosted its holdings in Danaher Co. (NYSE:DHR) by 0.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 157,638 shares of the conglomerate’s stock after purchasing an additional 437 shares during the quarter. Cambridge Trust Co.’s holdings in Danaher were worth $16,256,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc raised its position in Danaher by 1.4% during the 3rd quarter. Vanguard Group Inc now owns 44,738,984 shares of the conglomerate’s stock worth $4,861,338,000 after buying an additional 605,018 shares during the last quarter. BlackRock Inc. raised its position in Danaher by 0.9% during the 3rd quarter. BlackRock Inc. now owns 43,427,529 shares of the conglomerate’s stock worth $4,718,836,000 after buying an additional 396,818 shares during the last quarter. FMR LLC raised its position in Danaher by 3.5% during the 3rd quarter. FMR LLC now owns 21,739,751 shares of the conglomerate’s stock worth $2,362,241,000 after buying an additional 728,725 shares during the last quarter. Putnam Investments LLC raised its position in Danaher by 1.4% during the 3rd quarter. Putnam Investments LLC now owns 6,476,522 shares of the conglomerate’s stock worth $703,739,000 after buying an additional 91,519 shares during the last quarter. Finally, Flossbach Von Storch AG raised its position in Danaher by 3.2% during the 3rd quarter. Flossbach Von Storch AG now owns 5,729,830 shares of the conglomerate’s stock worth $622,603,000 after buying an additional 180,025 shares during the last quarter. Hedge funds and other institutional investors own 77.79% of the company’s stock.
A number of equities analysts have commented on the stock. Cowen restated a “buy” rating and set a $110.00 price objective on shares of Danaher in a research report on Monday, January 7th. Needham & Company LLC assumed coverage on shares of Danaher in a research report on Wednesday, January 2nd. They set a “buy” rating and a $114.00 price objective for the company. Royal Bank of Canada reaffirmed a “hold” rating and set a $102.00 price target on shares of Danaher in a research note on Wednesday, December 19th. Finally, Robert W. Baird lowered their price target on shares of Danaher from $116.00 to $114.00 and set an “outperform” rating on the stock in a research note on Friday, October 19th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $113.08.
NYSE:DHR opened at $109.25 on Monday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.07 and a current ratio of 1.47. Danaher Co. has a fifty-two week low of $91.84 and a fifty-two week high of $111.10. The firm has a market cap of $76.57 billion, a PE ratio of 24.17, a P/E/G ratio of 2.01 and a beta of 0.99.
Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 29th. The conglomerate reported $1.28 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.01. Danaher had a net margin of 13.33% and a return on equity of 11.64%. The business had revenue of $5.40 billion for the quarter, compared to analysts’ expectations of $5.33 billion. During the same period in the prior year, the company posted $1.19 EPS. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, equities research analysts expect that Danaher Co. will post 4.78 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 25th. Investors of record on Friday, December 28th were paid a $0.16 dividend. The ex-dividend date of this dividend was Thursday, December 27th. This represents a $0.64 dividend on an annualized basis and a yield of 0.59%. Danaher’s payout ratio is 14.16%.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Zolmax and is the property of of Zolmax. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://zolmax.com/investing/cambridge-trust-co-grows-position-in-danaher-co-dhr/2890897.html.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
See Also: How dollar cost averaging works
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.